Evidence map›Paper›PMID 36653660›Full record

ArticleCardiovascular and interventional radiology2023

Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response.

Κ Malagari, Th Kiakidis, Hip Moschouris, M Deutsch, S Tanteles, Eir Pantou, I Panagiotou, J Koskinas, G K Glantzounis, A Alexopoulou and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Κ Malagari2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece. kmalag@otenet.gr.ORCID http://orcid.org/0000-0002-1391-0965
Th Kiakidis2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
Hip MoschourisDepartment of Tzanion, General Hospital Pireus, Pireus, Greece.
M DeutschSecond Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
S Tanteles2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
Eir Pantou2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
I PanagiotouPalliative Care, Agios Savvas Anticancer Hospital, Athens, Greece.
J KoskinasUniversity Hospital of Ioannina, Ioannina, Greece.
G K GlantzounisUniversity Hospital of Ioannina, Ioannina, Greece.
A AlexopoulouSecond Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
D Filippiadis2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
E Brountzos2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
N Kelekis2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.

Funding

The study was supported by 'Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation 50
6 · The paper itself

Abstract

purposeThe primary objectives of this study were to evaluate safety, and efficacy of Transarterial Chemoembolization (TACE) using doxorubicin-loaded radiopaque microspheres (DC Bead LUMI™) for the treatment of early and intermediate stage Hepatocellular Carcinoma (HCC) not amenable for curative treatments. Distribution of the microspheres was correlated with results post embolization. MATERIALS AND

methodsThis was a prospective, single arm, open label study. The primary outcome measures were distribution of the radiopaque microspheres as showed by computerized tomography (CT) and local response measured by modified Response Evaluation Criteria (mRECIST) after Magnetic Resonance Imaging (MRI). Secondary measures were Time to Progression (TTP) and Overall Survival (OS).

resultsFifty patients were enrolled over 36 months. Median age was 69.0 years; mean sum of target lesions diameters was 78.6 ± 36.8 mm. There were no Grade 4 or 5 adverse events (AEs). At 6 months Complete Response (CR) (18%), Partial Response (PR) (62%), Objective Response OR (80%) and Stable Disease (SD) (20%) were recorded. Before embolization, Diffusion Weighted Imaging (DWI) showed high signal (restricted diffusion). Post procedure, patients with dense deposition (< 5 mm distance of microsphere aggregations) showed 100% absence of enhancement and no restriction in 30.6%. Median TTP was 8.3 months. TTP for patients with CR was 13.3 months and 7.2 and 5.6 for PR and SD, respectively. At 6 and 36 months, survival was 94% and 34%, respectively.

conclusionDC Bead LUMI™ is well tolerated and effective in early and intermediate stage HCC with maximal necrosis obtained in dense deposition in the target.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAgedAntibiotics, AntineoplasticDoxorubicinHumansMicrospheresProspective StudiesTreatment OutcomeAntibiotics, AntineoplasticDoxorubicinBarcelona clinic liver cancer (BCLC)DC bead LUMI™Drug eluting microspheresHepatocellular carcinoma (HCC)Radiopaque loadable microspheres

Identifiers

PMID36653660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.